查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1523255

微生物組治療市場報告：2030 年趨勢、預測與競爭分析

Microbiome Therapeutic Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

微生物組治療趨勢和預測

預計到 2030 年，全球微生物組治療市場將達到 11 億美元，2024 年至 2030 年複合年成長率為 32.4%。該市場的主要驅動力是微生物組治療研發中策略合作的數量不斷增加以及目標疾病盛行率的快速上升。全球微生物組治療市場的未來看起來充滿希望，艱難梭菌、克隆氏症、發炎性腸道疾病和糖尿病市場都有機會。

按細分領域進行微生物組治療

該研究包括按類型、應用和地區分類的全球微生物治療的預測。

微生物組治療市場洞察

Lucintel 預測，由於專注於發現 FMT 其他治療用途的研究和開發不斷增加，FMT 在預測期內將繼續佔據更大的佔有率。

在這個市場中，艱難梭菌預計將經歷最高的成長。

由於該地區目標人口不斷成長，北美在整個預測期內仍將是最大的地區。

常問問題

Q1.市場規模為：

A1. 到 2030 年，全球微生物組治療市場預計將達到 11 億美元。

Q2.市場成長預測是多少：

A2. 2024年至2030年，全球微生物組治療市場預計將以32.4%的複合年成長率成長。

Q3.影響市場成長的主要促進因素是：

A3. 該市場的主要驅動力是微生物組治療研發中策略合作的增加以及目標疾病盛行率的快速增加。

Q4.市場的主要細分市場是：

A4. 微生物組治療市場的未來充滿希望，艱難梭菌、克隆氏症、發炎性腸道疾病和糖尿病市場充滿機會。

Q5.市場的主要企業是：

A5. 微生物治療領域的主要企業有：

  • OpenBiome
  • Seres Therapeutics
  • Locus Biosciences
  • 4D Pharma
  • Enterome
  • Finch Therapeutics
  • Intralytix
  • Microbiotica
  • Second Genome
  • Rebiotix

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預測，由於致力於發現 FMT 的其他治療用途的研究和開發不斷增加，FMT 在預測期內將繼續成為一個更大的細分市場。

Q7. 未來五年預計哪些地區的市場成長最大？

A7. 由於該地區的目標人口不斷成長，北美在整個預測期內仍將是最大的地區。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章全球微生物組治療市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球微生物組治療市場趨勢（2018-2023）與預測（2024-2030）
  • 全球微生物組治療市場：按類型
    • FMT
    • 微生物醫學
  • 全球微生物組治療市場：依應用分類
    • 艱難梭菌（C. difficile）
    • 克隆氏症
    • 發炎性腸道疾病
    • 糖尿病
    • 其他

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球微生物組治療市場（按地區）
  • 北美微生物組治療市場
  • 歐洲微生物組治療市場
  • 亞太微生物組治療市場
  • 其他地區微生物組治療市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
  • 全球微生物組治療市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球微生物組治療市場的產能
    • 全球微生物組治療市場的合併、收購和合資企業
    • 認證和許可

第7章主要企業概況

  • OpenBiome
  • Seres Therapeutics
  • Locus Biosciences
  • 4D Pharma
  • Enterome
  • Finch Therapeutics
  • Intralytix
  • Microbiotica
  • Second Genome
  • Rebiotix
簡介目錄

Microbiome Therapeutic Trends and Forecast

The future of the global microbiome therapeutic market looks promising with opportunities in the c. difficile, crohn's disease, and inflammatory bowel disease, and diabetes markets. The global microbiome therapeutic market is expected to reach an estimated $1.1 billion by 2030 with a CAGR of 32.4% from 2024 to 2030. The major drivers for this market are rising number of strategic collaborations for microbiome therapeutics for R&D and surge in the prevalence of target disease.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Microbiome Therapeutic by Segment

The study includes a forecast for the global microbiome therapeutic by type, application, and region.

Microbiome Therapeutic Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • FMT
  • Microbiome Drug

Microbiome Therapeutic Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • C. Difficile
  • Crohn's Disease
  • Inflammatory Bowel Disease
  • Diabetes
  • Others

Microbiome Therapeutic Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Microbiome Therapeutic Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies microbiome therapeutic companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the microbiome therapeutic companies profiled in this report include-

  • OpenBiome
  • Seres Therapeutics
  • Locus Biosciences
  • 4D Pharma
  • Enterome
  • Finch Therapeutics
  • Intralytix
  • Microbiotica
  • Second Genome
  • Rebiotix

Microbiome Therapeutic Market Insights

Lucintel forecasts that FMT will remain larger segment over the forecast period due to rising R&D focusing on developments to discover other therapeutic applications of FMT.

Within this market, c. difficile is expected to witness the highest growth.

North America will remain the largest region over the forecast period due to growing target population in the region.

Features of the Global Microbiome Therapeutic Market

Market Size Estimates: Microbiome therapeutic market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Microbiome therapeutic market size by type, application, and region in terms of value ($B).

Regional Analysis: Microbiome therapeutic market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the microbiome therapeutic market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the microbiome therapeutic market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the microbiome therapeutic market size?

Answer: The global microbiome therapeutic market is expected to reach an estimated $1.1 billion by 2030.

Q2. What is the growth forecast for microbiome therapeutic market?

Answer: The global microbiome therapeutic market is expected to grow with a CAGR of 32.4% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the microbiome therapeutic market?

Answer: The major drivers for this market are rising number of strategic collaborations for microbiome therapeutics for R&D and surge in the prevalence of target disease.

Q4. What are the major segments for microbiome therapeutic market?

Answer: The future of the microbiome therapeutic market looks promising with opportunities in the c. difficile, crohn's disease, and inflammatory bowel disease, and diabetes markets.

Q5. Who are the key microbiome therapeutic market companies?

Answer: Some of the key microbiome therapeutic companies are as follows:

  • OpenBiome
  • Seres Therapeutics
  • Locus Biosciences
  • 4D Pharma
  • Enterome
  • Finch Therapeutics
  • Intralytix
  • Microbiotica
  • Second Genome
  • Rebiotix

Q6. Which microbiome therapeutic market segment will be the largest in future?

Answer: Lucintel forecasts that FMT will remain larger segment over the forecast period due to rising R&D focusing on developments to discover other therapeutic applications of FMT.

Q7. In microbiome therapeutic market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to growing target population in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the microbiome therapeutic market by type (FMT and microbiome drug), application (c. difficile, crohn's disease, inflammatory bowel disease, diabetes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Microbiome Therapeutic Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Microbiome Therapeutic Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Microbiome Therapeutic Market by Type
    • 3.3.1: FMT
    • 3.3.2: Microbiome Drug
  • 3.4: Global Microbiome Therapeutic Market by Application
    • 3.4.1: C. difficile
    • 3.4.2: Crohn's disease
    • 3.4.3: Inflammatory Bowel Disease
    • 3.4.4: Diabetes
    • 3.4.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Microbiome Therapeutic Market by Region
  • 4.2: North American Microbiome Therapeutic Market
    • 4.2.1: North American Microbiome Therapeutic Market by Type: FMT and Microbiome Drug
    • 4.2.2: North American Microbiome Therapeutic Market by Application: C. difficile, Crohn's disease, Inflammatory Bowel Disease, Diabetes, and Others
  • 4.3: European Microbiome Therapeutic Market
    • 4.3.1: European Microbiome Therapeutic Market by Type: FMT and Microbiome Drug
    • 4.3.2: European Microbiome Therapeutic Market by Application: C. difficile, Crohn's disease, Inflammatory Bowel Disease, Diabetes, and Others
  • 4.4: APAC Microbiome Therapeutic Market
    • 4.4.1: APAC Microbiome Therapeutic Market by Type: FMT and Microbiome Drug
    • 4.4.2: APAC Microbiome Therapeutic Market by Application: C. difficile, Crohn's disease, Inflammatory Bowel Disease, Diabetes, and Others
  • 4.5: ROW Microbiome Therapeutic Market
    • 4.5.1: ROW Microbiome Therapeutic Market by Type: FMT and Microbiome Drug
    • 4.5.2: ROW Microbiome Therapeutic Market by Application: C. difficile, Crohn's disease, Inflammatory Bowel Disease, Diabetes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Microbiome Therapeutic Market by Type
    • 6.1.2: Growth Opportunities for the Global Microbiome Therapeutic Market by Application
    • 6.1.3: Growth Opportunities for the Global Microbiome Therapeutic Market by Region
  • 6.2: Emerging Trends in the Global Microbiome Therapeutic Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Microbiome Therapeutic Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Microbiome Therapeutic Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: OpenBiome
  • 7.2: Seres Therapeutics
  • 7.3: Locus Biosciences
  • 7.4: 4D Pharma
  • 7.5: Enterome
  • 7.6: Finch Therapeutics
  • 7.7: Intralytix
  • 7.8: Microbiotica
  • 7.9: Second Genome
  • 7.10: Rebiotix